With investment signs “care”

by ApoMantho costume

share behavior From the Hellenic Stock Exchanges Group (HEXAE) It goes from good to better eventually moving with the normal standards you should have for what it stands for because the group’s income comes from the total turnover that happens each day in the market and not from the short-term mainstream.

In general, it should not be particularly affected by downward momentum, unless of course we have a general trend caused by something serious and difficult to reverse that can cause the market to “wither” for a long period of time. Of course there is no such thing, so the stock took its technical downside percentage from highs of €4,525 and then quickly responded above the €4 mark.

In the past, it would not only follow the downward momentum with the brakes broken, but also stay lower, unable to take the subsequent upward correction of the market.

Therefore, we see in the 3-day chart that the stock touched the €3.845 support, then made intensive attempts to collect losses, heading towards the €4.20 threshold. Breaking the price above that will push the stock once again to the bullish momentum, to hit the €4.525 resistance once again. However, the stock is shown, through the Price Volume Pattern Indicator (PVP) technical indicator, to execute volume-volume moves that are only found in serious index-heavy companies. From the looks of it so far, the new “guard” at the helm of the stock has a solid track record in investment management.

Signs of investment ‘interest’ with strong trading volumes and high buying pressure can also be found in the chart analysis of Listed pharmaceutical company only. Lavipharm (LAVI) In addition to the very good image of its shares on the board of directors, it now appears that it has radically changed its capital and size with the financial results of 2022 giving very strong fundamental support for the coming years. Already with the rapid financing of its investment plan following the successful capital raise, it is bearing fruit significantly with the first two months of 2023 bringing total group turnover to €10.34m from €8.02m, representing a strong growth of +29.1% compared to the same period last year.

Also, the transdermal clonidine system, which was acquired by Lavipharm on 12/21/2022, already in the first two months of 2023 generated sales in the Italian market of €1.2 million, further illuminating the total restricted figure of €7 million. announced by management for 2023. We are talking here about a product that leaves a profit margin of more than 55%. At the same time, the group is also moving very quickly in its medical cannabis product development plan, even hiring new employees to be ready to start strong in the last quarter of 2023.

But there is also a dynamic element that reveals the fruitful euphoria this year has reached the group. Therefore, for the first time in Lavipharm’s history, the plant will not be closed in August, but will operate normally due to increased orders for fentanyl patches. At the same time, the information indicates that another very important news is being prepared, if all goes well, the group will announce on May 10, in the presentation it will give to the Institutional Investors Association.

Charting now, the stock in recent sessions has found itself inside the solid base of buyers extending from €0.395 to €0.368. An area that has the potential to push the share price above the chart escape point of €0.414, re-targeting the level from €0.48 to €0.50, which, as everything shows, will pass very soon.